Glucagon-like peptide 1 receptor agonists in end-staged kidney disease and kidney transplantation: A narrative review.

Humans Hypoglycemic Agents / adverse effects Glycated Hemoglobin Kidney Transplantation / adverse effects Diabetes Mellitus, Type 2 / diagnosis Liraglutide / adverse effects Kidney Failure, Chronic / diagnosis Weight Loss Obesity / drug therapy Glucagon-Like Peptide-1 Receptor / agonists
Blood glucose Diabetes mellitus End stage kidney disease Glucagon like peptide 1 receptor Hemoglobin A1c Kidney transplantation

Journal

Nutrition, metabolism, and cardiovascular diseases : NMCD
ISSN: 1590-3729
Titre abrégé: Nutr Metab Cardiovasc Dis
Pays: Netherlands
ID NLM: 9111474

Informations de publication

Date de publication:
06 2023
Historique:
received: 21 12 2022
revised: 22 03 2023
accepted: 27 03 2023
medline: 17 5 2023
pubmed: 27 4 2023
entrez: 26 4 2023
Statut: ppublish

Résumé

Glucagon-like peptide 1 receptor agonists (GLP-1RA) improve glycemic control and promote weight loss in type 2 diabetes (DM2) and obesity. We identified studies describing the metabolic benefits of GLP-1RA in end-staged kidney disease (ESKD) and kidney transplantation. We searched for randomized controlled trials (RCTs) and observational studies that investigated the metabolic benefits of GLP-1RA in ESKD and kidney transplantation. We summarized the effect of GLP-1RA on measures of obesity and glycemic control, examined adverse events, and explored adherence with therapy. In small RCTs of patients with DM2 on dialysis, liraglutide for up to 12 weeks lowered HbA1c by 0.8%, reduced time in hyperglycemia by ∼2%, lowered blood glucose by 2 mmol/L and reduced weight by 1-2 kg, compared with placebo. In prospective studies inclusive of ESKD, 12 months of semaglutide reduced HbA1c by 0.8%, and contributed to weight losses of 8 kg. In retrospective cohort studies in DM2 and kidney transplantation, 12 months of GLP-1RA lowered HbA1c by 2%, and fasting glucose by ∼3 mmol/L compared with non-use, and in some reports, weight losses of up to 4 kg were described. Gastrointestinal (GI) side effects were most commonly reported, with hypoglycemia described with GLP-1RA in hemodialysis, particularly in those using insulin. GLP-1RA are growing in popularity in those with DM2 and obesity. In small RCTs and observational cohort studies modest glycemic and weight benefits have been described in ESKD and transplantation, but GI side effects may limit adherence. Larger and longer term studies of GLP-1RA remain important.

Identifiants

DOI: 10.1016/j.numecd.2023.03.023 PMID: 37100640
pubmed: 37100640
pii: S0939-4753(23)00143-6
doi: 10.1016/j.numecd.2023.03.023
pii:
doi:

Substances chimiques

Hypoglycemic Agents 0
Glycated Hemoglobin 0
Liraglutide 839I73S42A
Glucagon-Like Peptide-1 Receptor 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1111-1120

Subventions

Organisme : CIHR
Pays : Canada

Informations de copyright

Copyright © 2023 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest KKC has received honoraria for delivering certified medical education from the CPD Network, and the Canadian Medical and Surgical Knowledge Translation Group. TK has received honoraria for speaking engagements from Novo Nordisk Canada, Eli-Lily Canada.

Auteurs

Kristin K Clemens (KK)

Department of Medicine, Division of Endocrinology and Metabolism, Western University, 268 Grosvenor Street, N6A 4V2, London, Ontario, Canada; Department of Epidemiology and Biostatistics, Western University, 1465 Richmond Street, N6G 2M1, London, Ontario, Canada; Centre for Diabetes, Endocrinology and Metabolism, St. Joseph's Health Care London, 268 Grosvenor Street, N6A 4V2, London, Ontario, Canada; ICES Western, 800 Commissioners Road East, N6A 5W9, London, Ontario, Canada; Lawson Health Research Institute, 750 Base Line Road East, Suite 300, N6C 2R5, London, Ontario, Canada; Department of Medicine, Western University, 800 Commissioners Road East, N6A 5W9, London, Ontario, Canada. Electronic address: kristin.clemens@sjhc.london.on.ca.

Jaclyn Ernst (J)

Department of Medicine, Western University, 800 Commissioners Road East, N6A 5W9, London, Ontario, Canada.

Tayyab Khan (T)

Department of Medicine, Division of Endocrinology and Metabolism, Western University, 268 Grosvenor Street, N6A 4V2, London, Ontario, Canada; Centre for Diabetes, Endocrinology and Metabolism, St. Joseph's Health Care London, 268 Grosvenor Street, N6A 4V2, London, Ontario, Canada.

Sonja Reichert (S)

Department of Family Medicine, Western University, 1465 Richmond Street, N6G 2M1, London, Ontario, Canada.

Qasim Khan (Q)

Department of Medicine, Division of Gastroenterology, Western University, 800 Commissioners Road East, N6A 5W9, London, Ontario, Canada.

Heather LaPier (H)

Centre for Diabetes, Endocrinology and Metabolism, St. Joseph's Health Care London, 268 Grosvenor Street, N6A 4V2, London, Ontario, Canada.

Michael Chiu (M)

Department of Medicine, Division of Nephrology, Western University, 800 Commissioners Road East, N6A 5W9, London, Ontario, Canada.

Saverio Stranges (S)

Department of Epidemiology and Biostatistics, Western University, 1465 Richmond Street, N6G 2M1, London, Ontario, Canada; Department of Medicine, Western University, 800 Commissioners Road East, N6A 5W9, London, Ontario, Canada; Department of Family Medicine, Western University, 1465 Richmond Street, N6G 2M1, London, Ontario, Canada.

Gurleen Sahi (G)

Schulich School of Medicine and Dentistry, Western University, 1151 Richmond Street, N6A 5C1, London, Ontario, Canada.

Fabio Castrillon-Ramirez (F)

Schulich School of Medicine and Dentistry, Western University, 1151 Richmond Street, N6A 5C1, London, Ontario, Canada.

Louise Moist (L)

Department of Epidemiology and Biostatistics, Western University, 1465 Richmond Street, N6G 2M1, London, Ontario, Canada; Lawson Health Research Institute, 750 Base Line Road East, Suite 300, N6C 2R5, London, Ontario, Canada; Department of Medicine, Division of Nephrology, Western University, 800 Commissioners Road East, N6A 5W9, London, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Glucagon-like peptide 1 receptor agonists in...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hypoglycémiants › Glucagon-like peptide 1 receptor agonists in...
questionsmedicales.fr › Facteurs biologiques › Toxines biologiques › Produits terminaux de glycation avancée › Protéines glyquées › Protéine glycosylée sérique › Hémoglobine glycosylée › Glucagon-like peptide 1 receptor agonists in...
questionsmedicales.fr › Procédures de chirurgie opératoire › Procédures de chirurgie urogénitale › Procédures de chirurgie urologique › Transplantation rénale › Glucagon-like peptide 1 receptor agonists in...
questionsmedicales.fr › Maladies endocriniennes › Diabète › Diabète de type 2 › Glucagon-like peptide 1 receptor agonists in...
questionsmedicales.fr › Hormones gastrointestinales › Peptides glucagon-like › Glucagon-like peptide 1 › Liraglutide › Glucagon-like peptide 1 receptor agonists in...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Insuffisance rénale chronique › Défaillance rénale chronique › Glucagon-like peptide 1 receptor agonists in...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Mensurations corporelles › Poids › Modifications du poids corporel › Perte de poids › Glucagon-like peptide 1 receptor agonists in...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Obésité › Glucagon-like peptide 1 receptor agonists in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur hormone gastrointestinale › Récepteurs des peptides similaires au glucagon › Récepteur du peptide-1 similaire au glucagon › Glucagon-like peptide 1 receptor agonists in...